ArticleClinical cancer research : an official journal of the American Association for Cancer Research2011
Is cytomegalovirus a therapeutic target in glioblastoma?
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- Memory inflation: Beyond the acute phase of viral infection.Cell proliferation · 2024Review
- Development of a Human Cytomegalovirus (HCMV)-Based Therapeutic Cancer Vaccine Uncovers a Previously Unsuspected Viral Block of MHC Class I Antigen Presentation.Frontiers in immunology · 2019Article
- Lack of cytomegalovirus detection in human glioma.Virology journal · 2017Article
- Repurposing existing agents as adjunct therapies for glioblastoma.Neuro-oncology practice · 2016Article
- Perspectives on investigational drugs and immunotherapies for glioblastoma.Expert opinion on investigational drugs · 2016Article
- T cell engineering as therapy for cancer and HIV: our synthetic future.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2015Review
- Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and science.Expert review of molecular diagnostics · 2014Review
- Disruption of Bcl-2 and Bcl-xL by viral proteins as a possible cause of cancer.Infectious agents and cancer · 2014Review
- Engineering T cells for cancer: our synthetic future.Immunological reviews · 2014Article
- Personalized treatment strategies in glioblastoma: MGMT promoter methylation status.OncoTargets and therapy · 2013Review
- Mutations in glioblastoma oncosuppressive pathways pave the way for oncomodulatory activity of cytomegalovirus.Oncoimmunology · 2013Article
- Vaccine-based immunotherapy for glioblastoma.CNS oncology · 2013Review
- Role of infectious agents in the carcinogenesis of brain and head and neck cancers.Infectious agents and cancer · 2013Article
- Advances in the management of glioblastoma: the role of temozolomide and MGMT testing.Clinical pharmacology : advances and applications · 2013Article
- RNA interference-mediated targeting of human cytomegalovirus immediate-early or early gene products inhibits viral replication with differential effects on cellular functions.Journal of virology · 2012Article
- Cytomegalovirus and Mucoepidermoid carcinoma: A possible causal relationship? A pilot study.Journal of oral and maxillofacial pathology : JOMFPArticle
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several investigators have now demonstrated the expression of genes unique to cytomegalovirus (CMV) in malignant gliomas. Many of these genes promote oncogenesis, alter tumor microenvironment, and serve as immunologic targets. Is the level of CMV infection within tumor cells sufficient to drive important oncogenic or immunosuppressive processes? Can CMV serve as a target for therapeutic intervention?
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.